Lilly(US:LLY) GLP1减重宝典·2025-09-28 11:57Core Viewpoint - Eli Lilly has terminated a Phase 2b obesity trial for bimagrumab, which was intended to evaluate its efficacy both as a monotherapy and in combination with its main GLP-1/GIP drug, tirzepatide, before any participants were recruited [4][6]. Summary by Sections Trial Termination - The trial was initially planned to recruit 180 adults with obesity or overweight and type 2 diabetes, but was halted due to strategic business reasons [4]. - The status of the trial changed from "not yet recruiting" to "withdrawn," indicating a significant shift in the company's research strategy [6]. Ongoing Research - Despite the termination of the trial, bimagrumab is still being studied in another ongoing Phase 2 trial, which evaluates its efficacy alone or in combination with tirzepatide in the obese population, with results expected in 2026 [6]. Comparative Study Results - A related Phase 2 study presented at the American Diabetes Association meeting showed that patients receiving a combination of bimagrumab and semaglutide (Novo Nordisk's GLP-1 drug) had a significantly higher percentage of fat loss compared to those on semaglutide alone, with over 90% of weight loss in the combination group coming from fat [6].